ILAR’s advisory body, the ILAR Council, serves four principal functions:
- to provide program direction and strategic planning;
- to oversee information and communication programs (e.g., the ILAR website and the quarterly ILAR Journal);
- to oversee studies, reports, workshops, and other projects; and
- to direct ILAR’s international programs.
The ILAR Council meets for two days twice annually.
Margaret S. Landi, Chair
Chief of Animal Welfare, Ethics and Strategy
Associate Professor of Molecular and Comparative Pathobiology
Johns Hopkins University
Joseph J. DeGeorge
Bianca Holdings, LLC
Scientific Director, Head of Toxicology and Laboratory Animal Medicine
Johnson and Johnson, Janssen Pharmaceuticals
University of Michigan Medical School
Paul A. Locke
Associate Professor, Department of Environmental Health and Engineering
Director, DrPH Program in Environmental Health Sciences
Johns Hopkins Bloomberg School of Public Health
Program Director of the Global Health Program
Chief Wildlife Veterinary Medical Officer
Smithsonian Conservation Biology Institute
Associate Vice Chancellor for Research Administration and Institutional Compliance
University of Massachusetts Lowell
Barbara Natterson Horowitz
Professor of Medicine
University of California, Los Angeles
Regents Professor of Pathology & Infectious Diseases
Senior Director, Global Health
Washington State University
Senior Scientist and Director, Marine Stress Ocean Health
Anderson Cabot Center for Ocean Life
The New England Aquarium
Lawrence B. Schook
Edward William and Jane Marr Gutsgell Professor of Animal Sciences and Radiology
University of Illinois at Urbana-Champaign
Professor of Comparative Medicine and of Ophthalmology and Visual Science
Yale School of Medicine
Department of Comparative Medicine
Dr. Margaret S. Landi is Chief of Animal Welfare, Ethics and Strategy for GlaxoSmithKline. Her role is to provide leadership, guidance, and set policies as Chief Veterinarian for GSK. As Risk Owner for Animals she is responsible to ensure that the quality of animal work is independent of location of study conductance, there is compliance with Corporate Policy 403 on the Care, Welfare and Treatment of Animals, consistency in practices associated with all aspects of the animal care, and use programs where GSK works with animals. Margaret has a VMD and a Masters in Bioethics from the University of Pennsylvania and is a Diplomate in the American College of Laboratory Animal Medicine (ACLAM) and Past-President of the organization. She has worked on review committees of the National Institutes of Health (NIH), has led special site visit teams for NIH committees and is a past ad-hoc member of AAALAC. She is on the Board for the Scientists Center for Animal Welfare and the Chimp Haven Board of Directors. Margaret serves currently as the Chair of the Council for the Institute of Laboratory Animal Research, part of the NASEM. Recent areas of presentations and publications are in the application of global principles for laboratory animals in an international arena with differing laws, cultures, regulations and policies and application of moral considerability in ethical review processes.
Dr. Cory Brayton, DVM is a Diplomate of the American College of Laboratory Animal Medicine (ACLAM), and of the American College of Veterinary Pathologists (ACVP). She served as president of ACVP in 2014. Dr. Brayton is associate professor of molecular and comparative pathobiology at the Johns Hopkins University School of Medicine, in Baltimore, MD. Her research focuses on phenotyping and pathology in diverse translational research areas, including cancer, aging, immunology, infectious diseases and she serves as the director of the Phenotyping Core. She received her DVM from Cornell University, and did postdoctoral research and pathology training in New York City at the Animal Medical Center, Cornell University Medical College, and The Rockefeller University. At The Rockefeller University (1989-1992), she became specifically interested in genetically engineered mice (GEM) models in translational research, and in their pathology and characterization (phenotyping). Her areas of expertise and additional research interests include the spontaneous pathology and genetics of research mice, as well as the impacts of infectious and other environmental factors on disease expression and research outcomes in diverse model systems. Dr. Brayton’s primary teaching interest is to improve and promote understanding of model organism biology and pathology, especially as it is relevant to translational research. She has developed, directed, co-directed and lectured in symposia, conferences, courses and workshops relevant to phenotyping, pathology, genetics of mice and other laboratory animals, in the US and abroad. She has authored and coauthored books, chapters and invited reviews on mouse biology and pathology. She has served as Co-editor in chief of the ILAR Journal since 2012.
Dr. Joseph J. DeGeorge co-founded Bianca Holdings, LLC and serves as a Principal Partner responsible for pharmaceutical development consulting following retirement from Merck &Co. Inc in 2017. He joined Merck in 2004 as Vice President of Global Safety Assessment. From September of 2010, he served as Global Head of Safety Assessment and Laboratory Animal Resources for Merck Research Laboratories with global responsibility for non-clinical safety testing and evaluation in support of pharmaceutical discovery and development and from November of 2016 as Vice President, Preclinical Development Drug Safety. He has served on or chaired committees on drug discovery, drug candidate selection, early and late development, and development and post marketing drug safety. In addition to his position with Merck, he also serves as the PhRMA Coordinator for ICH Safety Topics (2004-present) and has participated in development of numerous ICH Guidances as PhRMA’s representative on ICH Safety and Multidisciplinary Expert Working Groups. He is a Council member for Institute of Laboratory Animal Research (ILAR) at the National Academy of Sciences, and has served on the Environmental Protection Agency Science Advisory Boards, most recently as a toxicology expert on Hydraulic Fracturing Water Quality Research Advisory Panel.
Before joining Merck, he served as Vice President of Preclinical Safety Evaluation at Novartis Pharmaceuticals and as the Global Chair for the Research and Development Safety Assessment Committee, with responsibility for oversight of first in human studies. Prior to Novartis, he was employed at the Food and Drug Administration (FDA) (1989-2002), where he held the position of Associate Director for Pharmacology and Toxicology in the Center for Drug Evaluation and Research (1996-2002) with responsibility for pharmacology and toxicology policy development and implementation. During his tenure at FDA he served on numerous policy and technical committees: Chair for CDER's Carcinogenicity Assessment Committee, CDER's Pharmacology and Toxicology Coordination Committee, the preclinical lead for the FDA Genomics and Proteomics Task Force, as a member of the International Life Sciences Institute (ILSI) Risk Science Institute Thresholds Assessment Committee, the ILSI-Health and Environmental Sciences (HESI) Alternatives to Carcinogenicity Testing Committee and the ILSI-HESI Emerging Issues Committee, as CDER’s technical representative to the Presidential Commission on Risk Assessment and CDER’s lead to the NIEHS-National Toxicology Program Academia, Industry, and Government Partnership for Evaluation and Validation of Transgenic Models for Carcinogenicity Testing. He also was CDER's ICH Safety Coordinator and lead for numerous Safety Expert Working Groups (1994 - 2002).
Dr. DeGeorge was a Senior Staff Fellow at the National Institutes of Health, National Institute on Aging, Laboratory of Neurosciences, where he worked on development of in vivo functional and structural brain imaging probe. He held a received postdoctoral training as a Fellow at the University of North Carolina, Chapel Hill, NC with a joint appointment at the Burroughs Wellcome Research Institute, Research Triangle Park, NC, where he focused on neural cell signaling and second messenger systems. Dr. DeGeorge received his Ph.D. in Pharmacology from the State University of New York/Upstate Medical Center, and his B.S. in Biology at the State University of New York, Albany.
Dr. Michael DuVall joined Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson in 2012 and is currently a Scientific Director and the US Head Toxicology and Laboratory Animal Medicine. Before joining Johnson & Johnson, Dr. DuVall was an Associate Director and Toxicology Project Lead in Preclinical Safety Evaluation at Abbott Laboratories and a Toxicology Study Director at Covance Laboratories. Michael received his DVM from Texas A&M University (1988) and his PhD from the College of Veterinary Medicine at the University of Minnesota (1993). He completed his post-doctoral training in the Cystic Fibrosis Center and Department of Anesthesiology at the University of Alabama at Birmingham where he studied the effects of reactive oxygen and nitrogen species on epithelial chloride and sodium channel protein function. Throughout his professional career, Michael has been a strong advocate of the ethical use of animals in research and has been active on multiple IACUCs. He is currently the Chairman of the Johnson & Johnson Animal Care and Use Council.
Dr. Robert Dysko has been a faculty member of the Unit for Laboratory Animal Medicine (ULAM) at the University of Michigan since 1990.During those 29 years, he has had many major responsibilities for the Unit including oversight of all campus animal facility design and construction projects, direction of the rodent health surveillance program, membership on the university's and the Ann Arbor Veterans Affair's animal care and use committees, and director of the program for training graduate veterinarians in laboratory animal medicine and comparative medical research. From July 2012 - June 2017 he was the fourth Director in ULAM's 50-year history. He has been active in the American Association for Laboratory Animal Science, serving on its Executive Board from 2008-2012, and in the role of President in 2011; the American College of Laboratory Animal Medicine, serving on its Board of Directors from 2000-2003; and the American Association of Veterinary Medical Colleges, serving on its Board of Directors from 2013-2017 as the at-large representative for Departments of Comparative Medicine. He has been a member of the ILAR Roundtable since 2013, and currently serves as its chair.
Dr. Paul A. Locke, an environmental health scientist and attorney, is an Associate Professor at the Johns Hopkins Bloomberg School of Public Health in the Department of Environmental Health and Engineering. He holds a joint appointment in the Department of Health Policy and Management. Dr. Locke has an MPH from Yale University School of Medicine, a DrPH from the Johns Hopkins University Bloomberg School of Public Health and a JD degree from Vanderbilt University School of Law. At Hopkins, Dr. Locke leads an integrated research, practice and teaching program. His program focuses on research-to-practice initiatives to better protect public health, especially in advancing evidence-based in vitro toxicology and radiation protection policy at federal and international organizations. He has published widely in both law reviews and scientific and policy journals, and has developed three cross-disciplinary courses in environmental law and policy and animal law. Dr. Locke also directs the School’s Doctor of Public Health program in Environmental Health Sciences and a certificate program in Humane Sciences and Toxicology Policy. Dr. Locke is admitted to practice law in the state of New York and the District of Columbia, the Southern District Court of New York and is a member of the bar of the United States Supreme Court. He is also a member of the Science Board of the American Public Health Association (APHA). He is the recipient of the Yale School of Public Health Alumni Service Award and the American Public Health Association Environment Section Distinguished Service Award.
Dr. Anne Maglia is the Associate Vice Chancellor for Research Administration and Institutional Compliance at the University of Massachusetts Lowell. She oversees the Office of Institutional Compliance, the Office of Research Administration, and the Research Support Services group. Her primary responsibility is to build the research portfolio while ensuring effective administration of the university’s sponsored research portfolio and compliance with terms and conditions, policies, laws and regulations relating to the conduct of research. She previously served at the National Science Foundation as a Program Director and Animal Welfare Officer. Prior to NSF, she was an Associate Professor of Biological Sciences at Missouri University of Science and Technology where her research program focused on amphibian skeletal development and biodiversity. Dr. Maglia served on the ILAR Roundtable, the Governing Board of the American Society of Ichthyologists and Herpetologists, and the Executive Committee of the Society for Integrative and Comparative Biology. She holds a B.S. in Pre-Veterinary Medicine from Ohio University, an M.S. in Biology from East Tennessee State University, a Ph.D. in Ecology and Evolutionary Biology from the University of Kansas, and is a certified Project Management Professional.
Dr. Suzan Murray is a board-certified zoo veterinarian at the Smithsonian Conservation Biology Institute (SCBI) and serves as both the program director of the Global Health Program and as the SCBI’s Chief Wildlife Veterinary Medical Officer. She leads an interdisciplinary team engaged in worldwide efforts to address health issues in endangered wildlife and combat emerging infectious diseases of global significance, including zoonotic diseases. Dr. Murray also acts as the Smithsonian liaison to the Foreign Animal Disease Threat and Pandemic Preparedness subcommittees of the White House’s Office of Science and Technology. Dr. Murray’s work focuses on providing clinical care to free-ranging wildlife, pathogen detection, advanced diagnostics, training of international veterinarians and other health professionals, capacity building, and collaboration in infectious disease research at the human-wildlife-domestic animal interface. She previously served as chief veterinarian for the Smithsonian’s National Zoo and has a wealth of clinical knowledge and experience with wildlife and zoo animals both free ranging and in human care. Dr. Murray earned a bachelor’s degree from Amherst College in 1984 and completed her veterinary degree in 1991 from Tufts University. After a surgical internship, she completed a residency in zoological medicine at the Smithsonian’s National Zoo in 1995 and became a Diplomate of the American College of Zoological Medicine (DACZM) in 2000. Dr. Murray has been either the principal investigator or co-principal investigator on several research grants, including Morris Animal Foundation, Smithsonian Endowment, Smithsonian Women’s Committee, and James Bond Funds.
Dr. Barbara Natterson-Horowitz is a Visiting Professor in Harvard University’s Department of Human Evolutionary Biology and Professor of Medicine
in the UCLA Division of Cardiology. She co-directs UCLA’s Evolutionary Medicine Program. Dr. Natterson-Horowitz studied evolutionary biology as an undergraduate and graduate student, receiving bachelor’s and master’s degrees from Harvard. She attended UC San Francisco for medical school followed by post-graduate training at UCLA including internal medicine residency and chief residency, and cardiology fellowship with advanced training in heart failure and cardiac imaging. She has been a member of the UCLA Division of Cardiology since 1993 and served as Director of Imaging for the UCLA Cardiac Arrhythmia Group. In 2012, she published the NY Times bestselling book, Zoobiquity, which makes the case for a species-spanning approach health. Zoobiquity was a Finalist in the American Association for the Advancement of Science (AAAS)'s Excellence in Science Books Award, Discover Magazine Best Book of 2012, and the China Times BestBook of 2012. It has been translated into seven languages and has been the common read at universities across the country. In September 2019, Dr. Natterson-Horowitz will keynote the Nobel Assembly's Nobel Conference in Stockholm, Sweden. The theme of the 2019 conference be the identification and application of scientific insights from the natural world to human health. In the same month, her new book, Wildhood, a comparative and phylogenetic exploration of the developmental transition from puberty to mature adulthood, will be published.
Dr. Guy Palmer holds the Jan and Jack Creighton Endowed Chair at Washington State University (WSU) where he is Regents Professor of Pathology & Infectious Diseases. The founding director of WSU’s Paul G. Allen School for Global Animal Health, he leads interdisciplinary health research as the Senior Director of Global Health. He also serves as the President of Global Animal Health-Tanzania and as Chair of WSU Global Health-Kenya.
Dr. Palmer currently directs global health programs in east and west Africa and Central America. He holds a joint appointment as Professor of Life Sciences and Bioengineering at the Nelson Mandela African Institution of Science and Technology in Tanzania and directs the Bill & Melinda Gates Foundation supported Integrated PhD Program between WSU and the Mandela Institution. Dr. Palmer also holds adjunct appointments with the University of Nairobi, the Center for Emerging and Re-emerging Infectious Diseases at the University of Washington, and the College of Veterinary Medicine at Kansas State University.
Dr. Palmer was elected to the National Academy of Medicine in 2006, is a Medical Sciences Fellow of the American Association for the Advancement of Science, and is a founding member of the Washington State Academy of Sciences, where he served as President from 2012-13. He serves on the State of Washington Advisory Board for the US Global Leadership Coalition, the Executive Roundtable of the Washington Global Health Alliance, Advisory Board for the Biosecurity Research Institute.
Dr. Palmer earned a BS (Biology, summa cum laude) and a DVM, both from Kansas State University and a PhD (Infectious Diseases) from WSU. He is board-certified in anatomic pathology. He has been recognized with the Poppensiek Professorship at Cornell, the IBM Professorship at Colby, the Schalm Lecturership at the University of California, the Distinguished Scientist Lectureship at NIH, the Science in Medicine Lectureship at the University of Washington, Ramsey Lectureship at Iowa State University, and the Merck Award for Creativity. Dr. Palmer received WSU’s Sahlin Award for Research, Scholarship, and the Arts in 2008, the Eminent Faculty Award in 2013, and the Alumni Achievement Award in 2017. He received the Distinguished Alumnus and Alumni Fellow Awards from Kansas State University in 2009 and 2011, respectively. He holds honorary doctorates from the University of Bern (Dr. Med.Vet, 2011) and Kansas State (PhD 2016).
Dr. Rosalind Rolland is the Director of the Marine Stress and Ocean Health Program, and a Senior Scientist at the Anderson-Cabot Center for Ocean Life at the New England Aquarium (NEAq) in Boston, Massachusetts. She also holds a Research Faculty appointment at the School for the Environment at the University of Massachusetts-Boston. Dr. Rolland received her B.S. degree in Natural Sciences from the University of Wisconsin-Madison, and her doctorate in Veterinary Medicine from Tufts University School of Veterinary Medicine. Prior to joining the NEAq in 2000, Dr. Rolland worked as a Conservation Scientist at the World Wildlife Fund and as Science Director for the Center for Conservation Medicine at Tufts University School of Veterinary Medicine. Dr. Rolland has previously held faculty appointments at Tufts University, Harvard Medical School, MIT, and the University of North Carolina-Wilmington. She has served two terms on the Board of the North Atlantic Right Whale Consortium. Dr. Rolland’s focal interest over the course of her career has been on the intersection between the health of wildlife, the environment and human health. Her earlier research activities included investigating antibiotic resistance transfer through the food web and the effects of endocrine-disrupting chemicals in various wildlife species. Over the past two decades at the NEAq, Dr. Rolland’s research has focused on development of methods to study health, and reproductive and stress physiology in large whales in the wild. She pioneered validation and application of methods to quantify a panel of steroid and thyroid hormones in free-swimming whales using samples of scat, baleen and respiratory vapor (blow). She has led collaborative projects investigating diseases, marine biotoxins, and the effects of underwater noise on North Atlantic right whales. Dr. Rolland steered development of a method to visually monitor health of North Atlantic right whales, and used this data to model health trends of individual whales and the population over three decades. Her cetacean field research experience includes working on North and South Atlantic right whales, sperm whales, Blainville’s beaked whales, and bowhead whales. The goal of Dr. Rolland’s research program at the NEAq is to better understand the impacts of human activities on marine wildlife, and to use health trends in large whales as an indicator of the health of ocean ecosystems. Dr. Rolland is an author on over 60 scientific publications and she is the co-editor (with Dr. Scott Kraus) of the definitive book on right whales, The Urban Whale: North Atlantic Right Whales at the Crossroads published by Harvard University Press in 2007. Dr. Rolland’s research program has received widespread national and international attention in the popular press including stories by Science Magazine, the New York Times, Boston Globe, National Wildlife, National Public Radio, CBC Radio, BBC World News, Globe and Mail, Greenwire, New Scientist, Science Daily, and the Christian Science Monitor.
Dr. Lawrence B. Schook is an Edward William and Jane Marr Gutsgell Professor of Animal Sciences and Radiology and previously served as the Vice President for Research at the University of Illinois, overseeing the technology commercialization and economic development activities across the University’s three campuses (Urbana-Champaign, Chicago, Springfield). Schook is a recognized international scholar in comparative genomics and is known for leading the pig genome-sequencing project, which has provided researchers insights into human cancer and other chronic diseases. He is a noted entrepreneur who has launched two medical application startup companies and is a Fellow at the Academy for Entrepreneurial Leadership. He has served as an advisor to corporations, universities, and government agencies with respect to medical models, genomics, and animal biotechnology. Schook led the effort to develop UI LABS, a Chicago-based research and commercialization collaborative that spun out of the University, and is a founding Board member. He currently serves on the Boards of Trustees for Albion College, the National Academy of Sciences Institute for Laboratory Animal Science Council, the Current Water Innovation Cluster Board, and the Illinois Technology Association Internet of Things Council. He is a member of the Joint Center for Energy Storage Research (JCESR) Governance Board and co-chairs the Chicago Metro Metals Consortium’s Research & Innovation Subcommittee and the Illinois Manufacturing Laboratory Executive Committee. He previously served on the Board of Managers for the Fermi and Argonne National Laboratories, Illinois Governor Quinn’s Innovation Council, the Biotechnology Industry Organization (BIO) Board of Directors, the BIO Governing Board on Food and Agriculture, the Agricultural Biotechnology International Conference Foundation, and the boards of multiple biotechnology companies. He served as Chair for the International Swine Genome Sequencing Consortium, a pig genome sequencing collaboration among global academic, government, and industry representatives. Schook attended Albion College (BA, 1972; Distinguished Alumni Award, 1996) and received his MS and PhD from Wayne State University School of Medicine. He is an elected Fellow of the American Association for the Advancement of Science and was a Fulbright Distinguished Chair in genomics at the University of Salzburg. He has mentored 75 students and 20 postdoctoral fellows, has written more than 250 published works, has edited six books, and is founding editor of Animal Biotechnology.
Dr. Caroline Zeiss is a veterinary pathologist and laboratory animal veterinarian. She directs the Yale Mouse Research Pathology Core, and collaborates on multiple studies with Yale and external investigators in academia and industry. Her research focuses on mechanisms of neurodegeneration with a strong focus on translation of basic studies towards clinical relevance. Most recently, she has applied biomedical informatics, natural language processing and networks analysis to develop methods to improve preclinical translatability of animal research. In particular, she are interested in methods that can correlate interventional outcomes across human and animal species by intervention, drug class and choice of outcome measure. Dr. Zeiss has practiced as a laboratory animal clinician with a focus on non-human primate medicine since 2012, and has published multiple papers on non-human primate medicine and pathology. She consults with industry regarding efficacy and toxicity studies utilizing ophthalmic and neurologic disease models.